Immune checkpoint blockade (ICB) in cancer immunotherapy aids the immune system in recognizing and killing cancer cells [100] by targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA4), programmed death 1 (PD1), and programmed death-ligand 1 (PD-L1). Here, CD274 is linked to cancer.